Mitoxantrone Dose for Dogs and Cats

Mitoxantrone is administered intravenously at 5 mg/m2 every 21 days in dogs and 2.5 to 6.5 mg/m2 every 21 days in cats, as calculated using the Vetinuity mitoxantrone dose calculator below.

Doses

Indication	Species	Dose	Route and frequency
Malignant lymphoma, carcinoma, or mesothelioma	Dog	5 mg/m2	IV Every 21 days
Resistant lymphoma (with dacarbazine)	Dog	5 mg/m2	IV over 10 minutes Every 21 days
Malignant carcinoma or lymphoma	Cat	2.5-6.5 mg/m2	IV Every 21 days
Adjuvant therapy for mammary carcinoma	Cat	6 mg/m2	IV Every 21 days for 4 cycles

Dogs weighing 10 kg or less have a 5.8-fold increased relative risk of severe grade 3 or 4 neutropenia; an initial dose reduction should be considered.

Mitoxantrone can be given as an intravenous bolus with lower risk of severe extravasation injury compared to doxorubicin.

Indications and Dosing Protocols

In dogs, mitoxantrone is indicated as single-agent or combination chemotherapy for lymphoma, genitourinary carcinoma, transitional cell carcinoma, and malignant mesothelioma. Standard canine dosing is 5 mg/m2 IV every 21 days. For resistant canine lymphoma, mitoxantrone (5 mg/m2 IV over 10 minutes) combined with dacarbazine (600 mg/m2 IV over 5 hours) every 3 weeks achieved a 34 percent response rate. Combination regimens for genitourinary carcinoma incorporating mitoxantrone, radiation therapy, and NSAIDs achieved a median overall survival time of 510 days.

In cats, mitoxantrone is dosed at 2.5 to 6.5 mg/m2 IV every 21 days. In feline mammary carcinoma, adjuvant mitoxantrone at 6 mg/m2 IV every 21 days for 4 cycles post-mastectomy achieved a median disease-free interval of 360 days and median survival time of 480 days. For feline intermediate to large cell lymphoma, the CMOP protocol (cyclophosphamide, mitoxantrone, vincristine, prednisolone) demonstrated equivalence to CHOP, achieving a 66 percent response rate, median progression-free interval of 69 days, and median survival of 103 days.

Pharmacokinetics and Myocardial Safety

Mitoxantrone is an anthracenedione agent that exhibits multiexponential plasma clearance kinetics with a terminal half-life ranging from 38 hours to several days. The drug rapidly clears from plasma via extensive tissue sequestration, while elimination occurs slowly through both renal and biliary excretion, with biliary clearance predominated. Unchanged mitoxantrone is the primary drug moiety bound to tissues.

Unlike doxorubicin, which induces progressive, cumulative myocardial lesions at doses as low as 144 mg/m2 in dogs, mitoxantrone does not produce progressive morphological cardiotoxicity or clinical heart failure at maximum tolerated doses (2.58 to 5.15 mg/m2 IV every 3 weeks). This profile makes mitoxantrone a preferred alternative when cardiac sparing is required.

Toxicity Profile and Weight-Based Risk Factors

Myelosuppression is the primary dose-limiting toxicity in dogs, with neutrophil nadirs occurring around day 7 post-treatment. Canine patient weight strongly correlates with neutropenia severity: dogs weighing 10 kg or less face a 5.8-fold relative risk, and dogs weighing 15 kg or less face an 8.1-fold relative risk of developing grade 3 or 4 neutropenia compared to larger dogs. Hospitalization for clinical signs related to neutropenia occurred in 46 percent of dogs developing grade 3 or 4 toxicity, warranting initial dose reductions in small dogs.

In cats, observed toxicoses include anorexia, vomiting, diarrhea, lethargy, azotemia, leukopenia, sepsis, and rarely seizures. Older cats and cats exhibiting toxicities during the first 21-day cycle are significantly more likely to suffer adverse events during subsequent treatment cycles. In combination with cyclophosphamide (CYCLONE protocol), feline leukocyte and neutrophil nadirs consistently occur between days 2 and 10.

Administration Technique and Extravasation Safety

Mitoxantrone is logistically practical for feline patients because it can be safely administered as an intravenous bolus. Clinical evaluation of chemotherapy extravasation events demonstrated that accidental extravasation of mitoxantrone (n=2) resulted in no clinical tissue injury or necrosis, contrasting sharply with carboplatin and doxorubicin extravasations which required surgical debridement or amputation.

Ask Vetinuity

Vetinuity is a clinical assistant built by Brian Toncray, an emergency veterinarian, to assist clinicians with oncology treatment options, dose math, and medical record summaries.

Vetinuity explains clinical options with journal citations.

The veterinarian diagnoses and prescribes.

• Treatment options and drug doses, each with its journal citation
• Veterinary clinical decision support while the exam is happening